Lung cancer is one of the most common malignant tumors in the world. Although advanced therapies
have been applied for the treatment of lung cancer, the prolongation of overall survival is limited due to treatment
resistance. MicroRNAs (miRNAs) are a class of small non-coding, endogenous RNA molecules (about 19-23
nucleotides in length), which could regulate numerous human genes and play key roles in a variety of diseases.
MiRNAs are dysregulated in lung cancer and participate in tumor initiation, development and drug resistance.
Recent studies showed a new therapeutic strategy for cancer therapy based on miRNAs. In this review, we briefly
summarize one classic pathway of miRNAs in lung cancer, and discuss a new miRNA-based therapeutic strategy
to manage lung cancer.